Jan 29 (Reuters) - Insulin delivery device maker Beta Bionics said on Wednesday it raised $204 million in its initial public offering $(IPO.UK)$ at a valuation of about $700 million.
The U.S.-based company said it priced its IPO at $17 per share, the upper-end of its forecasted range of $16 to $17 per share.
The size of the offering was raised to 12 million shares from 10 million shares, the company said.
Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O had to lower their valuation targets.
Beta's shares will start trading on the Nasdaq under the symbol "BBNX" on Thursday.
BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.
(Reporting by Kritika Singh in Bengaluru; Editing by Savio D'Souza)
((Kritika.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。